Novonesis delivered 8% organic sales growth in the first nine months of 2025

Novonesis reported a robust 8% organic sales growth for the first nine months of 2025, showcasing a strong performance that prompted the company to narrow its full-year outlook upwards to a range of 7-8%, up from the previous 6-8% forecast. In a statement made on November 6, 2025, President & CEO Ester Baiget expressed satisfaction with the company's results, highlighting solid profitability despite facing significant currency challenges. The adjusted EBITDA margin stood at an impressive 37.3%, marking a slight increase from the previous quarter's 37.1%.

The growth was broad-based, with notable performance across all sales areas and both emerging and developed markets. The Food & Health segment led the charge with a 9% organic sales growth, while Planetary Health achieved an 8% increase. Emerging markets displayed particularly strong momentum, reporting 12% organic sales growth compared to 6% in developed markets.

The company also acknowledged the negative impact of exiting certain countries, which reduced organic sales growth by approximately 1 percentage point, a figure that was slightly higher in the previous quarter. However, price increases contributed positively by roughly 1 percentage point overall.

In terms of financial health, adjusted net profit surged by 22%, reinforcing the company's robust operational performance. The net interest-bearing debt to EBITDA ratio stood at 2.0x, underlining solid cash flow management with free cash flow before acquisitions reaching EUR 668.4 million.

Looking ahead, Novonesis expects mid-single-digit organic sales growth for the fourth quarter, bolstered by favorable trends from the third quarter, and aims to achieve an adjusted EBITDA margin toward the lower end of the 37-38% range amid ongoing currency pressures.

Novonesis' recent performance for the first nine months of 2025, showcasing an impressive 8% organic sales growth, reflects the company's robust operational strength and resilience in navigating challenges, including currency fluctuations. The upward revision of their full-year outlook, now projected between 7-8%, indicates a confident management team that is executing its strategic priorities effectively.

Several factors underpin this strong performance. Notably, the Food & Health segment showed organic sales growth of 9%, driven by robust demand that outpaced currency effects and the impact of exiting certain markets. Additionally, the company’s expansion in emerging markets, where it achieved a notable 12% growth, suggests strong future potential. Conversely, the developed markets exhibited a more modest but stable growth at 6%, indicative of Novonesis’ successful maintenance of its market share even in mature economies.

The company’s impressive adjusted EBITDA margin of 37.3%, along with a 22% increase in net profit, highlights operational efficiency and strong profitability. Coupled with a solid net interest-bearing debt to EBITDA ratio of 2.0, Novonesis appears to be well-positioned for growth without over-leveraging itself.

Investors should view Novonesis positively, as the company not only meets but exceeds its growth targets even amidst external pressures. The indication of mid-single-digit growth for the fourth quarter could yield substantial shareholder returns if the company continues on its growth trajectory. However, it is wise to monitor external factors, including currency headwinds and market volatility, which could impact future performance.

In conclusion, Novonesis presents a compelling investment opportunity, benefitting from solid fundamentals, a clear strategic vision for sustainable growth, and an essential focus on profitability. Analysts and investors should consider accumulating shares as the company continues to navigate and shape its landscape towards its ambitious 2030 targets.